PKM and ovarian cancer: Our study focused on the effects of compound 3K, a specific PKM2 inhibitor, in ovarian cancer cells, and we mechanistically demonstrated that the effects of compound 3K were mediated by the targeting of metabolism for therapeutic benefit.